X

Trial Profile

A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Namodenoson (Primary)
Indications Liver cancer
Focus Therapeutic Use
Sponsors Can-Fite BioPharma

Most Recent Events

25 Apr 2024 According to a Can-Fite Biopharma media release, the Company announced it published an article in the Experimental and Therapeutic Medicine Journal.
21 Nov 2023 Results published in the Can-Fite Biopharma Media Release
25 Oct 2022 Results presented in a Can-Fite Biopharma Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com